CONTRACTUAL ORIGIN OF THE INVENTION The United States Government has riqhts in this invention pursuant to Contract No. W-31-109-ENG-38 between the U.S. Department of Enerqy and Arqonne National Laboratory.

BACKGROUND OF THE INVENTION This invention is related to a method and apparatus for the concentration and separation of actinide values from samples containing these and other elements. More specifically, the invention relates to a method and apparatus for the quantitative recovery of actinide values from biological and environmental samples. Still more specifically, the invention relates to a method for the quantitative recovery and detection of actinide values from biological samples such as urine, blood and feces and from -environmental samples such as soil and water and to an apparatus for accomplishing the same.

The wide-scale use of nuclear technology, both in power production and in the manufacture of nuclear weapons, necessitates the periodic monitoring of bio¬ logical and environmental samples for the presence of selected actinide elements; e.g. Th, U, Np, Pu, Am and Cm. ^" The most common types of samples assayed are urine and fecal material. Recent world events such as the power reactor explosion at Chernobyl in the USSR, point up the need for quick, effective and accurate methods for monitoring environmental samples of soil and water to determine the degree of distribution and concentration of the actinide elements, as a group and individually. A number of proceedures for the determination of the actinide plutonium in urine are disclosed in Mikro- chimica Acta 1978 1, pages 79 to 88. As discussed therein, proceedures for the preconcentration of ex¬ tremely small amounts of Pu (about 10~H - 10~12g) f _rθ m the vast excess of matrix substances present in urine samples include: precipitation reactions, absorption on glass fibre, extraction, extraction chromatogrophy and ion exchange. Of these, the precipitation reactions provides the most economical results.

As described in the article, the present method for recovering Pu from urine samples reguires the ad¬ dition of nitric acid and a small amount of calcium

ions and phosphoric acid to the sample which is then heated for about 3 hours to diqest the proteinaceous material normally found in urine, releasing the Pu. Concentrated ammonia solution is then added to co-pre¬ cipitate calcium phosphate and the Pu. The precipitate is then dissolved in HNO3 and evaporated to dryness several times to wet-ash any remaininq organic matter. Solid sodium nitrite and nitric acid are added to this residue and the mixture is heated to prepare a nitric

10 acid sample solution suitable for anion exchanqe. After passing the sample solution through the anion exchange column to recover the Pu, the column is washed several times before the Pu eluted with a dilute HCl/HF solution. Following evaporation to dryness, the residue is dis¬ solved in an appropriate solution and the Pu is electro- deposited. The alpha count is then obtained to deter¬ mine the guantity of Pu present.

From the above, it is obvious that the Pu recovery process is complex, time consuming and expensive. While

20. the process will also recover Np and Th, it will not re¬ cover other actinides, if present. Furthermore, re¬ covery of the various actinides individually is difficult should the detection of each actinide be desired. Also needed is a method- for the quantitative analysis of actinide values which may be found in water

and soil samples which is quick, accurate and relatively inexpensive.

U.S. Patent No. 4,548,790 dated October 22, 1985 describes a qroup of neutral bifunctional organophos- phorous compounds broadly described as alky (phenyl)- N,N-dialkylcarbamoylmethylphosphine oxides (hereinafter referred to as CMPO) which are useful for the recovery of actinide and lanthanide values from acidic solutions containing these and other metal values. The combin- ation of the CMPO extractants with a phase modifier such as tri-n-butyl phosphate (hereinafter referred to as TBP) in a normal paraffin hydrocarbon diluent (NPH) diluent is described in U.S. Patent No. 4,574,072, dated March 4, 1986. Both patents are assigned to the common assignee and are incorporated herein by reference.

SUMMARY OF THE INVENTION A method and apparatus has been developed for the isolation and separation of actinide values, which is applicable to a wide range of biological and environ— mental samples which utilized this new group of extrac¬ tants. - The method is relatively rapid, highly sepcific, and flexible in regard to the number and selection of actinides which can be isolated.

The method of the invention, for guantitatively detecting actinide values which may be present in

biological or environmental samples, comprises treating the sample, if necessary, to concentrate and release the actinide values, forming an acidic sample solution containing the actinide values, passing the sample solu¬ tion through a separation column of a CMPO in TBP on an inert substrate, whereby the actinides are taken up by the separation column, passing an ammonium oxalate solution through the column to elute the actinide ele¬ ments, and detectinq the presence and quantity of the actinide elements. This method is being referred to as ABBEX (actinide fcύoassay b_ifunctional extraction) .

By the selection of eluents, it is possible to separately elute the various actinide values from the column so that each element can be quantitatively determined.

The separation column of the invention has an upper, open-topped cylindrical portion for receiving the solutions, a tubular body portion containing an inert porous support material on which is absorbed CMPO diluted in TBP for separating the actinides from the sample solutions and a funnel-shaped lower portion having a lower opening for draining the solutions from the column.

The method of the invention is suitable for the guantitative recovery of actinides from biological samples

such as urine, feces and blood and from environmental samples such as water and soil. The essential difference in the method between the various samples is in the pre¬ paration of the sample to facilitate actinide recovery.

It is therefore one object of the invention to provide a method for the quantitative recovery of ac¬ tinide values from biological and environmental sources. It is another object of the invention to provide a method for the guantitative recovery of actinides from biological and environmental samples in which the ac¬ tinide values can be recovered separately. It is still another object of the invention to provide a method for the quantitative recovery of actinide values from bio¬ logical samples such as urine, feces, and blood. Finally, it is the object of the invention to guantitatively recovery actinide values from environment samples such as soil and water.

DETAILED DESCRIPTION OF THE DRAWINGS

Figure 1 is a flow diagram of the method of the in- vention for the separation of actinide values from urine.

Figure 2 is a diagram of the method of the invention for the seguential separation of the actinide values from the separation column.

Figure 3 is a drawinq of the apparatus of the invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT These and other objects of the invention, for quantitatively detecting actinide values present in a sample, consists of preparing the sample to concentrate and release the actinide. The manner in which a sample is prepared will depend upon the sample under study and will be discribed in detail below. For example, a 600 ml urine sample, is made about 1.6 M in nitric acid and about 50 grams of calcium ion and about 1 ml of concen- ^' trated phosphoric acid are added to form a digestion solution. The solution is heated for about 3 hours at just below boiling temperature to destroy any protein or cellular material in the sample and release the acti¬ nides. To" this solution is added about 100 ml of con¬ centrated ammonium hydroxide to form monobasic calcium phosphate which precipitates out, carrying with it the actinide values in the sample. After separation the precipitate is dissolved in sufficient nitric acid to form an acid solution of at least 1.0 M. This solution is made 0.5 M in aluminum nitrate and about 0.5 ml of 0.1 M ferrous nitrate is added to reduce any Np(V) to Np(IV), forming an acidic sample solution. The acidic sample solution is then passed through a separation column of 0.75 M octyl(phenyl)-N, N-diisobutylcarbamoyl- methylphosphine oxide dissolved in tri-n-butyl phosphate

on an inert substrate whereby the actinides are selec¬ tively taken up by the separation column, passing a 1 M HNO3 wash solution through the column to remove other values from the column, passing an 0.1 M ammonium hydro¬ gen oxalate strip solution through the column to elute the actinide values from the column, adding sufficient ammonium chloride to the eluent to form an electrolytic solution, passing a current through the solution to electrodeposit the actinide values, and detecting the presence and quantity of actinide values with an alpha spectrometer.

Alternatively, actinide values can be quantit¬ atively recovered from urine samples without the precipi¬ tation step. The sample is first acidified to from 1.0 to 2.0 M, preferably 1.6 M, in nitric acid and heated for about 3 hours to digest any protein on cellular material. The digested sample is then acidified to at le ^~ ast 1 M in HNO3 or 6 M in HCl and the acid solution is passed through a pre-column of the inert substrate material without the extractant. The precolumn adsorbs material from the urine, which would otherwise plug the separation column, preventing the flow of the sample solution through the column. The purified acidified urine sample can then be passed through the separation column where the actinides are taken up. A pre—column

bed size of 20 ml together with a separation column of 20 ml, is sufficient for a urine sample of 600 ml.

The digested sample solution may be acidified with a strong mineral acid which may be from about 1.0 to 10.0 M in HNO3 or from about 6.0 to 12.0 M in HCl. Solutions below 1.0 M in nitric acid or 6.0 M in HCl will not load the actinides onto the separation column.

The aluminum nitrate in the acidic solution may range from about 0.01 to 0.5 M, preferably 0.1 M. Al- ^" though not absolutely necessary, the aluminum nitrate provides for better absorption of the tri-valent Cm and Am values on the column from the acidic solution.

The ferrous nitrate is added in an amount suffi¬ cient to reduce any Np(V) to Np(IV). .Generally, about 0.5 ml of a 0.1 M Fe(II) nitrate solution is sufficient for a 600 ml urine sample.

The preferred CMPO is octyl(phenyl)N,N-disobutyl- carbamoylmethylphosphine oxide (hereinafter referred to as OøD(iB)CMPO) which has been dissolved in TBP, although any of the CMPO extractants described in the before mentioned patent will be satisfactory. Prefer- abley, the TBP contains from 0.5 to 1.0 M OøD(iB)- CMPO, most preferably about 0.75 M. The inert support material may be any hydrophobic chromatographic support material such as Amberlite XAD-4, 7 or 16, silica gel.

Porasil ^® or Zorbax Sil ^® . The mesh size of the support may range from 50 to 500 mesh preferably about 100 to 125 mesh.

Referring now to Figure 3, the separation column 10 of the invention consists of a cylindrical portion 12 having an open top 14 for receiving the sample solutions, a central tubular-shaped body portion 16 having a lower porous plug 18 for supporting the support material, the body portion containing inert porous support material 20 on which is adsorbed a CMPO diluted in TBP for ex¬ tracting the actinide values from the solutions and other values, and a funnel-shaped bottom portion 22 having an outlet 24 for draining the solutions from the column A column which have been found satisfactory for the recovery of actinides from urine samples as pre¬ pared above, has a bed volume of about 1 ml.

One advantage of the method and apparatus of the invention is that the various actinides can be eluted separately from the extraction column and recovered individually. As shown in the flow diagram of Figure 3, the extraction column is loaded with the actinide values by passing the acidic sample solution through the column. A first wash of several bed volumes of 1 M HNO3 followed by a second wash of several bed volumes of 6 M HCl will remove essentially all non-actinide

elements. A third wash of several bed volumes of 3 M HCl will strip Am and Cm values from the column. This is followed by several volumes of 1 M HCl to strip the Th. The Pu is stripped with a solution of 0.5 M HCl containing 0.1 M ascorbic acid while a solution of 0.5 M HCl and 0.1 M HF brings down the Np. A final solution of 0.1 M ammonium oxalate strips the remaining uranium values. The various fractions can then be electro- deposited and counted with an alpha spectrometer. Alternatively, sequential separation can also be accomplished by placing a second column before the CMPO column. This column containing tricaprylmethylammonium chloride sorbed on a inert substrate. This column will remove the tetravalent actinides such as Th, Pu and Np, which are stripped with 6 M HCl, 6 M HCl-0.1 M hydro- guinone, and 0.5 M HCl-0.1 M HF respectively. The original load and wash from this column is used to feed th ^" e CMPO column where the uranium and trivalent acti¬ nides are absorbed. The trivalent actinides are stripped with 2 M HCl while the uranium is stripped with 0.1 M ammonium hydrogen oxalate. The various fractions can then be electrodeposited and counted as described herein after.

Sample size will depend upon the biological or en¬ vironmental sample being tested but must contain suffi-

cient actinide values to come within the detection limits. For example, a 0.6 to 1.0 liter urine specimen is sufficient as is a 200 gm fecal specimen. A water sample may be from .5 to 1 liter while a 100-500 gm soil sample should suffice.

Pretreatment of the sample for actinide recovery will, as stated before, depend upon the source of the sample. The preparation of a urine sample has been des¬ cribed in detail. A fecal sample must first be dried, for example, at 500 ^β C in a muffle furnace, to form an ash which is mostly calcium phosphate. This ash in then dissolved in about 10 ml of 2 M HNO3 and 0.5 M aluminum nitrate, to which the Fe(II) ion is added to form the acidic sample solution. A water sample is acidified with nitric or hydrochloric acid to the proper concentration and passed through the separation column. Alternativel _r the water sample could be evaporated to reduce the volume before acidifying and column contact. Preparation of a soil sample would involve treatment with an acid, such as nitric or hydrochloric containing a small amount of HF to solubilize the actinides and dissolve silicon. The resulting mixture is then fil¬ tered and a small amount of aluminium nitrate is added to complex any fluoride ion remaining and the acidic solution is passed through the separation column as in the case of a urine or fecal sample.

Detection of the actinides is best done by an alpha spectrometer. Preferably a small amount of an electro¬ lyte, such has ammonium chloride, is added to the eluent and a current passed through the solution to deposit the actinides on a stainless steel disk. Alternatively, the eluent can be evaporated and an alpha count of re¬ duced accuracy made of the residue.

The following examples are given to illustrate the method of the invention and are not to be taken or limiting the scope of the invention as defined by the appended claims.

ABBEX COLUMN PREPARATION Unpurif.ied Amberlite ^® XAD-7, 100-120 mesh was soaked in distilled water over night. The material was slurried in water, allowed to settle in a column and washed several times in distilled water followed by several washes in methanol until the wash was clear of cloudiness. All traces of methanol are then removed.

Coating. Each 10 g of purified, dried XAD-7 resin requires 6.86 ml of 0.75 M_ O0D(iB)CMPO in TBP to pro¬ duce an approximately 90% coating (based on porosity). The 0.75 M 00D(iB)CMPO in TBP was prepared by dis¬ solving 3.06 g of O0D(iB)CMPO in TBP and diluting to 10.0 ml. The 6.9 ml of O0D( iB)CMPO/TBP solution was dissolved in 50 ml of methanol and added to a slurry of

10 g of purified XAD-7 in 50-100 ml of methanol. The mixture was gently heated and stirred to evaporate off the methanol while suspending the resin. When it be¬ came a paste, it was removed from the heat and pumped down in a vacuum desiccator at room temperature equipped with a solvent trap to remove the last traces of methanol until constant weight was reached. The dried, coated material is a grainy, fee-flowing powder.

EXAMPLE I

ID: About 0.4 g of the 00D(iB)CMPO/TBP-coated XAD-7 resin was loaded as an aqueous slurry into a 9" dispos¬ able glass Pasteur pipet (0.5 cm I.D.) fitted with a small glass wool plug. After settling (resin depth 5 cm) , the resin was covered with 3-5 mm depth of glass beads (diameter 0.2 mm). The column, which was fitted with a plastic funnel as a reservoir, was then con¬ ditioned by passing through it the following solutions (in the given order):

(1) 0.1 M NH4HC2O4, * 20 ml

20 (2) 2 M HNO3, * 35 ml

(3) 2 M HNO3 - 0.5 K Al(N0 ₃ )3, * 5-10 ml. Prior to the actual column separation step, the acti¬ nides are co-precipitated as a group on a basic calcium phosphate precipitate (containing >_ 50 mg Ca) by neu¬ tralizing a nitric acid-digested urine to which Ca ²⁺

and Pθ ~ have been added with NH^OH. The precipitated basic calcium phosphate was separated from the urine solution (by decantation and centri ugation) and then dissolved in nitric acid and ashed to destroy organic material. The ashed calcium phosphate residue was dis¬ solved in 10 ml of 2 M HNO3 - 0.5 M Al(N03)3 with gentle heating. In order to reduce Np(V) to Np(IV), about 0.5 ml of 0.1 M Fe(II)nitrate solution (in dilute HNO3 with hydrazinium and hydroxylammonium nitrate stabilizers) is added. After 10-15 minutes, this feed solution (10.5 ml) was passed through the O0D(iB)CMP0/TBP/XAD-7 column to extract the nitrate complexes of (III)-(IV)- and (VI)- valent actinides. Two-2 ml rinses with 2 ^ HNO3 0.5 M_ Al( 03)3 were successively added to the column. Two-2 ml washes with 1 M_ HN0 ₃ serve to wash Ca and Al salts (non-absorbed) out of the column as well as to remove any absorbed Fe(III) from the column. (Normally, a faint yellow color from weakly absorbed Fe(III) due to air oxidation of the added Fe(II) appears in the upper half of the column. This disappears guickly with the first portion of the 1 fl HNO3 wash. The appearance of a bright yellow color during the feed loading step in¬ dicates considerable oxidation of the Fe(II) to Fe(III). This latter condition may be accompanied by loss of column efficiency due to the uptake of Fe(III) and

failure to reduce Np(V) to Np(IV).) The extracted acti¬ nides were stripped from the column by eluting with 10 ml of 0.1 M NH4HC2O4. This strip solution is collected directly in an electroplating cell. After the addition of 2.5 ml of 5 M NH4CI electrolyte, the actinides were electrodeposited onto a polished stainless steel disk (cathode) by passing a current (initially 0.8 - 0.9 am¬ peres at 13 V) with a Pt wire-loop anode for 2.5 hours. Tests of the entire procedure were conducted with a mixed tracer solution of ²³⁶ U, ²³⁷ Np, 239 _{Pu an} 244 _Cm (about 3-6 dpm of each nuclide) added to 600 ml por¬ tions of various different urine specimens. The final electrodeposited samples were assayed for these nuclides by high resolution alpha spectroscopy with semiconductor detectors of known efficiency. The average recoveries of each nuclide from 12 replicates are presented in the following table:

TABLE I

Alpha—Particle

Nuclide Energy (MeV) Percentage Recovery'

²³⁶ U 4.49- 85 + 6

²³⁷ Np 4.7 (average) 85 + 12

²³⁹ Pu 5.15 86 + 6

^{2 4} Cm, 5.71 86 + 6

^a Average of three sets of four samples each. Uncer¬ tainties are standard deviations of the data distrib¬ utions. Lowest recovery: 50% ( ⁷ Np); highest recovery: 98% ( ²³⁹ Pu).

As can be seen from the preceedinq discussion and

Example, the method and apparatus of the invention pro¬ vide a quick, effective, accurate and inexpensive method and apparatus for the quantitative determination of acti¬ nides in biological and environmental samples.